Machine learning's next frontier: Epigenetic drug discovery

Machine learning's next frontier: Epigenetic drug discovery
Alexey Terskikh, Ph.D., associate professor in Sanford Burnham Prebys' Development, Aging and Regeneration Program and senior author of the study. Credit: Sanford Burnham Prebys

Machine learning's powerful ability to detect patterns in complex data is revolutionizing how we drive, how we diagnose disease and now, how we discover new drugs. Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images—allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more. The study was published in eLife.

"In order to identify the rare few candidates that induce desired epigenetic effects, scientists need methods to screen hundreds of thousands of potential compounds," says Alexey Terskikh, Ph.D., associate professor in Sanford Burnham Prebys' Development, Aging and Regeneration Program and senior author of the study. "Our study describes a powerful image-based approach that enables high-throughput epigenetic drug discovery."

Epigenetics refers to chemical tags on DNA that allow cellular machinery greater or less access to genes—thus altering . Nearly all changes in a cell, including reaction to a drug and environmental stress, are reflected by its epigenetic state. Several medicines that target are approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer, and researchers are working to find additional epigenetic-based therapies. However, drug discovery has been slowed by a lack of a high-throughput screening method: Scientists currently visualize epigenetic changes using special dyes and traditional microscopy methods.

In the study, the scientists trained a using a set of more than 220 drugs known to work epigenetically. The resulting method, called Microscopic Imaging of Epigenetic Landscapes (MIEL), was able to detect active drugs, classify the compounds by their molecular function, spot epigenetic changes across multiple and drug concentrations, and help identify how unknown compounds work. The scientists used the approach to identify epigenetic compounds that may be able to help treat glioblastoma, a deadly brain cancer.

"Our method is ready for immediate use by pharmaceutical companies looking to develop epigenetic drug screens," says Chen Farhy, Ph.D., a postdoctoral researcher in the Terskikh lab and first author of the study. "Industry and academic researchers working on mechanistic studies may also benefit from this method, as the algorithm can detect and categorize epigenetic changes induced by experimental treatments, genetic manipulations or other approaches."

Terskikh and his team are already using the algorithm to study epigenetic changes in aging cells, with the aim of developing compounds that promote healthy aging—the single greatest risk factor for disease. This work is conducted in collaboration with Sanford Burnham Prebys professor Peter Adams, Ph.D. Terskikh is also eager to broaden the technology from 2-D images to 3-D videos, which will expand the power of the approach.


Explore further

A quick path to antimalarial resistance

More information: Chen Farhy et al, Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape, eLife (2019). DOI: 10.7554/eLife.49683
Journal information: eLife

Citation: Machine learning's next frontier: Epigenetic drug discovery (2019, October 22) retrieved 17 November 2019 from https://medicalxpress.com/news/2019-10-machine-frontier-epigenetic-drug-discovery.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
9 shares

Feedback to editors

User comments